MedTrace Logo

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2022-03-14

No results posted yet for this study

Summary

This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.

Conditions

  • Platelet Aggregation Inhibitors
  • Aspirin
  • Ticagrelor
  • RNA

Interventions

DRUG

Aspirin

Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.

DRUG

Ticagrelor

Ticagrelor 90mg BID x 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Deepak Voora, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-01
Primary Completion
2016-12-05
Completion
2016-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278637 on ClinicalTrials.gov